ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Abstract Number: 0327

Lipoprotein(a) in Systemic Lupus Erythematosus Is Associated with History of Proteinuria and Renal Insufficiency
Abstract Number: 0328

Natural Language Processing to Identify Lupus Nephritis Phenotype in Electronic Health Records
Abstract Number: 0329

Racial and Ethnic Disparities in Risk of End-Organ Disease Following SLE Diagnosis in a Multi-Ethnic Cohort
Abstract Number: 0330

Serologic Phenotypes Distinguish SLE Patients with Myositis And/or Interstitial Lung Disease (ILD)
Abstract Number: 0331

Urinary MicroRNAs as Systemic Lupus Erythematosus Biomarkers and Its Potential for Accurate Assessment of Disease Severity
Abstract Number: 0332

Prevalence of Systemic Lupus Erythematosus in the United States: Updated Population Representative Estimates from the Medical Expenditure Panel Survey (MEPS) 2016-2018
Abstract Number: 0333

Validation of the 2019 European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) Classification Criteria for Systemic Lupus Erythematosus (SLE) in Hong Kong Chinese
Abstract Number: 0334

Association Between Systemic Lupus Erythematosus and Myasthenia Gravis: A Population-Based National Study
Abstract Number: 0335

Performances of Different Classification Criteria for Systemic Lupus Erythematosus in a Single Center Cohort from Turkey
Abstract Number: 0336

The Incremental Clinical Utility of a Multianalyte Assay Panel with Cell-Bound Complement Activation Products versus a Traditional ANA Testing Strategy for the Diagnosis and Treatment of SLE
Abstract Number: 0337

Rarity of Pneumocystis Jirovecii Pneumonia in Patients with Systemic Lupus Erythematosus Using a Real-world, Electronic Health Record
Abstract Number: 0338

Serum and Urine Galectin-9, IP-10 and SIGLEC-1 as Biomarkers of Disease Activity in Patients with Systemic Lupus Erythematosus
Abstract Number: 0339

Trends in Disparity by Age, Sex and Race for Systemic Lupus Erythematosus Patients
Abstract Number: 0340

Urinary L-selectin Predicts Disease Activity and Histological Changes in Lupus Nephritis
Abstract Number: 0341

Addition of Narrative Text Abstraction to ICD-Based Abstraction Significantly Improves Identification of Lupus Nephritis in Real-World Data

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].